Abstract
Diabetic retinopathy is one of the common ocular diseases. One of the pathological characteristic of proliferative diabetic retinopathy is retinal neovascularization which caused visual impairment in diabetic patients. With the anti-VEGF drugs applying in the clinic, it has become one of the main medical treatment of diabetic retinopathy. But it has its limitation. Researchers continue to explore new drug targeting for anti-angiogenesis and try combination therapy or customized treatment. There are many drug targets for anti-angiogenesis, such as promoting angiogenesis factor, integrins and matrix proteinases. Some drugs act on the typical tip cells which is much important in the process of angiogenesis differentiation and proliferation. Overall, these studies opened our view of anti-angiogenesis. The purpose of this article is to summarize the possible drug targets of angiogenesis and the key issues in the study of anti-angiogenic drugs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
